On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
On May 3, 2023, the U.S. FDA approved GlaxoSmithKline’s Arexvy as the first respiratory syncytial virus (RSV) vaccine…
On Apr. 27, 2023, a NIAID-led Phase 2 trial compared two Pfizer bivalent mRNA COVID-19 boosters found that…
On Apr. 27, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
On Mar. 20, 2023, NIH scientists announced that the magnitude and quality of a key immune cellï¾’s response…
On Mar. 20, 2023, some of the world’s leading makers of flu vaccines said they could make hundreds…
On Mar. 17, 2023, the Indonesia Ministry of Health notified WHO of the detection of a circulating vaccine-derived…
On Mar. 14, 2023, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the…
On Mar. 10, 2023, the U.S. Centers for Disease Control and Prevention (CDC) in a significant step toward…
On Mar. 6, 2023, Merck announced that the U.S. Food and Drug Administration had approved the addition of…
On Feb. 24, 2023, Moderna announced will make certain contingent development, commercial and regulatory milestone payments to the…
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
On Feb. 16, 2023, it was reported in the Lancet that protection from past infection against re-infection from…
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
On Feb. 14, 2023, scientists from the National Institute of Allergy and Infectious Diseases announced they had developed…
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…
On Feb. 2, 2023, a National Institutes of Health research group with extensive experience studying ebolavirus countermeasures successfully…
On Jan. 25, 2023, researchers at Oregon Health & Science University reported that Immunity from COVID-19 appears to…
On Jan. 18, 2023, the National Institutes of Health (NIH) announced that an investigational HIV vaccine regimen tested…
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
On Jan. 11, 2023, the U.S. Food and Drug Administration reported that a single booster dose with an…
On Jan. 5, 2023, Novavax announced that Spain�s Public Health Commission, Italy�s Ministry of Health, and France�s Haute…
Milestones in Polio illustrates the slow but steady advancements from its clinical description and discovery to widespread infection…
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
On Nov. 12, 2022, the World Health Organization (WHO) issued a Disease Outbreak News (DON) on the circulating…
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Dec. 15, 2022, the University of Oxford Oxfordï¾’s Ebola vaccine candidate has been shipped to Uganda, just…